Endogenous incretin levels and risk of first incident cancer: a prospective cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Endogenous incretin levels and risk of first incident cancer : a prospective cohort study. / Jujic, Amra; Godina, Christopher; Belting, Mattias; Melander, Olle; Holst, Jens Juul; Ahlqvist, Emma; Gomez, Maria F.; Nilsson, Peter M.; Jernstrom, Helena; Magnusson, Martin.
I: Scientific Reports, Bind 13, Nr. 1, 382, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Endogenous incretin levels and risk of first incident cancer
T2 - a prospective cohort study
AU - Jujic, Amra
AU - Godina, Christopher
AU - Belting, Mattias
AU - Melander, Olle
AU - Holst, Jens Juul
AU - Ahlqvist, Emma
AU - Gomez, Maria F.
AU - Nilsson, Peter M.
AU - Jernstrom, Helena
AU - Magnusson, Martin
PY - 2023
Y1 - 2023
N2 - Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmo Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 +/- 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82-0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.
AB - Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmo Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 +/- 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82-0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.
KW - PANCREATIC-CANCER
KW - DIABETES-MELLITUS
KW - SEX DISPARITIES
KW - CELL MASS
KW - GLUCOSE
KW - THERAPIES
KW - REGISTER
KW - PERIOD
U2 - 10.1038/s41598-023-27509-3
DO - 10.1038/s41598-023-27509-3
M3 - Journal article
C2 - 36611045
VL - 13
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 382
ER -
ID: 351197227